Serum amyloid A is not a marker for relapse of multicentric lymphoma in dogs

Merlo, Alexandre; Rezende, Bárbara Cristina Gagliano; Franchini, Maria Luísa; Monteiro, P. R. G; Lucas, Sílvia Regina Ricci

doi:10.1111/j.1939-165x.2008.00016.x

Cited by 9 publications

(5 citation statements)

References 21 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The technique was concluded to offer potential for disease monitoring but has not been developed commercially. The acute phase protein SAA was elevated in dogs with lymphoma, decreased with therapy, but was not seen to elevate at relapse ( 10 ). The authors concluded that SAA was not a useful marker of relapse in dogs with lymphoma.…”

Section: Serum Proteinsmentioning

confidence: 99%

The Current State of Clinical Application of Serum Biomarkers for Canine Lymphoma

Bryan

2016

Front. Vet. Sci.

View full text Add to dashboard Cite

Serum biomarkers of canine lymphoma activity for diagnosis, prognosis, and therapy monitoring have been of clinical interest for more than a decade. Tumor products, biochemical enzymes, cytokines, metabolic profiling, leakage enzymes, as well as serum proteins have been studied as biomarkers for lymphoma. Multiple biomarkers combined have been shown to be most sensitive and specific. C-reactive protein, thymidine kinase 1, and haptoglobin have been most extensively studied and commercialized in diagnostic tests, the TK Canine Cancer Panel and the Canine Lymphoma Blood Test. These tests have been evaluated either in cohorts of diseased and healthy dogs or in prospective studies of ill dogs, respectively, for application to clinical decision-making. Some evidence exists for application of these tests, but large-scale studies are lacking in a broad range of lymphoma forms. These biomarkers are commonly elevated at diagnosis and at relapse. Further study is necessary to determine if early intervention guided by biomarker elevation will improve quantity or quality of life for dogs with lymphoma.

show abstract

Section: Serum Proteinsmentioning

confidence: 99%

The Current State of Clinical Application of Serum Biomarkers for Canine Lymphoma

Bryan

2016

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

“…In dogs, causes of changes in APP serum concentrations include infectious, immunologic, traumatic, or neoplastic diseases 5 . Increased concentrations of positive APPs, such as C-reactive protein (CRP) and serum amyloid A (SAA), have been found in dogs with lymphoma and other hematologic malignancies 7,8,17 . Measurements of APPs can be used as a screening test for systemic response to an inflammatory stimulus and may be helpful to assess clinical progression and to monitor treatment of some neoplastic diseases 17 …”

Section: Introductionmentioning

confidence: 99%

“…5 Increased concentrations of positive APPs, such as C-reactive protein (CRP) and serum amyloid A (SAA), have been found in dogs with lymphoma and other hematologic malignancies. 7,8,17 Measurements of APPs can be used as a screening test for systemic response to an inflammatory stimulus and may be helpful to assess clinical progression and to monitor treatment of some neoplastic diseases. 17 Many reports can be found in human literature where APPs have been extensively studied in breast cancer at different stages and clinical presentations.…”

Section: Introductionmentioning

confidence: 99%

Serum Acute Phase Protein Concentrations in Female Dogs with Mammary Tumors

et al. 2009

View full text Add to dashboard Cite

Abstract. Acute phase proteins (APPs) are proteins whose concentrations in serum change after any inflammatory stimulus or tissue damage. The aim of the current study was to evaluate 3 positive APPs (Creactive protein, serum amyloid A, and haptoglobin) and 1 negative APP (albumin) in female dogs with mammary neoplasia. Acute phase proteins were studied in 70 female dogs aged 8-12 years in the following groups: healthy (n 5 10); mammary tumors in stages I (n 5 19), II (n 5 5), III (n 5 6), IV (n 5 5), and V (n 5 7); and with mammary neoplasia plus a concomitant disease (n 5 18). In animals with mammary neoplasia, significant increases of positive APPs were only detected in those that had metastasis or a neoplasm with a diameter greater than 5 cm and ulceration. Dogs with mammary neoplasia and a concomitant disease also had high C-reactive protein concentrations. Albumin concentration was decreased in animals with metastasis and with a concomitant disease. The results of the present study indicate that the acute phase response could be stimulated in female dogs with mammary gland tumors because of different factors, such as metastasis, large size of the primary mass, and ulceration or secondary inflammation of the neoplasm.

show abstract

“…The initial search yielded over 508 references, many of which were not specifically relevant to our topic. After the exclusion of irrelevant studies, 63 articles that appeared relevant to our aim and that met all study criteria were identified and fully reviewed . The main characteristics of the included studies are summarized in Table .…”

Section: Resultsmentioning

confidence: 99%

Conformity and controversies in the diagnosis, staging and follow‐up evaluation of canine nodal lymphoma: a systematic review of the last 15 years of published literature

Marconato

Polton

Sabattini

et al. 2016

Vet Comparative Oncology

View full text Add to dashboard Cite

Diagnostic methods used in the initial and post-treatment evaluation of canine lymphoma are heterogeneous and can vary within countries and institutions. Accurate reporting of clinical stage and response assessment is crucial in determining the treatment efficacy and predicting prognosis. This study comprises a systematic review of all available canine multicentric lymphoma studies published over 15 years. Data concerning diagnosis, clinical stage evaluation and response assessment procedures were extracted and compared. Sixty-three studies met the eligibility criteria. Fifty-five (87.3%) studies were non-randomized prospective or retrospective studies. The survey results also expose variations in diagnostic criteria and treatment response assessment in canine multicentric lymphoma. Variations in staging procedures performed and recorded led to an unquantifiable heterogeneity among patients in and between studies, making it difficult to compare treatment efficacies. Awareness of this inconsistency of procedure and reporting may help in the design of future clinical trials.

show abstract

Serum amyloid A is not a marker for relapse of multicentric lymphoma in dogs

Abstract: SAA is not a marker of relapse in dogs with multicentric lymphoma, nor does chemotherapy regimen affect SAA concentration.

Cited by 9 publications

References 21 publications

The Current State of Clinical Application of Serum Biomarkers for Canine Lymphoma

The Current State of Clinical Application of Serum Biomarkers for Canine Lymphoma

Serum Acute Phase Protein Concentrations in Female Dogs with Mammary Tumors

Conformity and controversies in the diagnosis, staging and follow‐up evaluation of canine nodal lymphoma: a systematic review of the last 15 years of published literature

Contact Info

Product

Resources

About